open access

Vol 5, No 4 (2001)
Prace oryginalne
Published online: 2001-10-03
Get Citation

Homocysteine and Hemostatic Risk Factors in Atherosclerosis in Patients with Primary Hypertension

Hanna Berent, Bożenna Wocial, Krystyna Kuczyńska, Małgorzata Raczkowska
Nadciśnienie tętnicze 2001;5(4):255-260.

open access

Vol 5, No 4 (2001)
Prace oryginalne
Published online: 2001-10-03

Abstract

Background No conclusions have been made so far in assessing the role of the so-called non-traditional risk factors in the onset or progression of atherosclerosis in patients with essential hypertension.The purpose of the study was to determine concentrations of homocysteine,von Willebrand factor (vWF),lipoprotein (a) - Lp(a),fibrinogen (Fb)and plasminogen activator inhibitor type 1 (PAI-1)in patients with essential hypertension and healthy subjects and to analyse the correlation between homocysteine level and the other tested parameters.
Material and methods The study group consisted of 37 patients with essential hypertension,14 women and 23 men (mean age 42,4 ±13,1 yrs)and 27 healthy volunteers, 15 women and 12 men (mean age 42,6 ±9,5 yrs).
Results Patients with essential hypertension had significantly higher homocysteine (8,7 ±2,4 mmol/L vs.6,8 ± ± 1,3 mmol/L;p <0,01),vWF (104,3 ±39,4%vs.73,6 ± ± 20,2%;p <0,05)and Fb (310,1 ±77,9 mg%vs.256,2 ± ± 54,8 mg%;p <0,02)concentrations as compared to control group.Concentrations of Lp(a)(14,2 ±14,2 mg% vs.17,6 ±8,5 mg%)and PAI-1 (26,7 ±18,2 ng/ml vs.21,8 ± ± 15,1 ng//ml)were similar in both groups.No correlation was observed between homocystein levels and vWF,Lp(a),Fb, PAI-1,age,diastolic and systolic blood pressure neither in subjects with essential hypertension nor in healthy volunteers.
Conclusions We suggest that the early onset of cardiovascular disease in patients with essential hypertension could be linked to elevated concentrations of homocysteine,Fb and vWF,which are considered to be major risk factors in atherosclerosis.

Abstract

Background No conclusions have been made so far in assessing the role of the so-called non-traditional risk factors in the onset or progression of atherosclerosis in patients with essential hypertension.The purpose of the study was to determine concentrations of homocysteine,von Willebrand factor (vWF),lipoprotein (a) - Lp(a),fibrinogen (Fb)and plasminogen activator inhibitor type 1 (PAI-1)in patients with essential hypertension and healthy subjects and to analyse the correlation between homocysteine level and the other tested parameters.
Material and methods The study group consisted of 37 patients with essential hypertension,14 women and 23 men (mean age 42,4 ±13,1 yrs)and 27 healthy volunteers, 15 women and 12 men (mean age 42,6 ±9,5 yrs).
Results Patients with essential hypertension had significantly higher homocysteine (8,7 ±2,4 mmol/L vs.6,8 ± ± 1,3 mmol/L;p <0,01),vWF (104,3 ±39,4%vs.73,6 ± ± 20,2%;p <0,05)and Fb (310,1 ±77,9 mg%vs.256,2 ± ± 54,8 mg%;p <0,02)concentrations as compared to control group.Concentrations of Lp(a)(14,2 ±14,2 mg% vs.17,6 ±8,5 mg%)and PAI-1 (26,7 ±18,2 ng/ml vs.21,8 ± ± 15,1 ng//ml)were similar in both groups.No correlation was observed between homocystein levels and vWF,Lp(a),Fb, PAI-1,age,diastolic and systolic blood pressure neither in subjects with essential hypertension nor in healthy volunteers.
Conclusions We suggest that the early onset of cardiovascular disease in patients with essential hypertension could be linked to elevated concentrations of homocysteine,Fb and vWF,which are considered to be major risk factors in atherosclerosis.

Get Citation

Keywords

homocysteine; von Willebrand factor; plasminogen activator inhibitor type 1; fibrinogen; lipoprotein (a); hypertension

About this article
Title

Homocysteine and Hemostatic Risk Factors in Atherosclerosis in Patients with Primary Hypertension

Journal

Arterial Hypertension

Issue

Vol 5, No 4 (2001)

Pages

255-260

Published online

2001-10-03

Bibliographic record

Nadciśnienie tętnicze 2001;5(4):255-260.

Keywords

homocysteine
von Willebrand factor
plasminogen activator inhibitor type 1
fibrinogen
lipoprotein (a)
hypertension

Authors

Hanna Berent
Bożenna Wocial
Krystyna Kuczyńska
Małgorzata Raczkowska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl